Australia is the first country in the world to legalise the medical use of psychedelics. But without a public subsidy, few Australians will be able to afford them.
Academic rigor, journalistic flair
Articles on Pharmaceutical Benefits Scheme
Displaying 1 - 20 of 31 articles
The government has missed a chance to better target cost cuts to certain patient groups, for certain medical conditions, and for generic drugs.
Anthony Albanese on Sunday formally launched Labor’s campaign, with promises for low paid women, and aspiring home buyers.
Changes in the latest federal budget will mostly affect people who need multiple medicines throughout the year, perhaps for chronic disease. But there are other ways to reduce drug costs.
The language used to describe medications is confusing, with multiple names for the same drug. A change to prescribing rules from today should go a long way to addressing this issue.
The Pharmacy Guild represents the owners of community pharmacies around the country. Their reach into every community and large political donations make them more powerful than other lobby groups.
Here’s how the Turnbull/Morrison government performed on hospitals, primary care, pharmaceuticals and private health insurance.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies’ own finances.
Wider availability of the cystic fibrosis drug Kalydeco since May 1, 2017 means younger patients can now access it.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
Should new understandings of how cancers develop and could be targeted mean we should change the way the scheme registers cancer drugs?
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Australians are picking up some of the slack of government belt-tightening by paying more for health, with experts concerned this could reduce the equity in Australia’s health system.
The off-label use of medicines is not illegal and it doesn’t mean regulators have specifically “disapproved” its use. But there are a number of issues to consider before using a medicine off-label.
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
Despite numerous leaks about impending changes to medicines policy, the budget showed savings of just $252.2 million over five years from adjusting the price of a small number of PBS-listed drugs.
The government is locked in a major battle with pharmacists as it looks for $3 billion in budget savings from the pharmaceutical supply chain.
The latest part of the TPP to be leaked is its investment chapter. And like almost everything we know about the secretive negotiations for the agreement, it provides plenty of cause for concern.
Australians make an average of 14 visits to the pharmacy for medicines and advice every year but most don’t know about the agreement that governs how we buy government-subsidised medicines from them.
Apart from proposing a co-payment for visiting doctors, the last federal budget also contained a proposal to increase the level of co-payments for medications. The government seems to have given little…
Top contributors
-
Professor of Health Economics, The University of Melbourne
-
Associate Professor in Public Health, La Trobe University
-
Professorial Fellow, University of Canberra
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Professor of Health Economics, The University of Melbourne
-
Professor of Health Economics, Flinders University
-
Adjunct Associate Professor, Menzies Centre for Health Policy, University of Sydney
-
Senior Lecturer law, ethics and sociology, Charles Sturt University
-
Professorial Research Fellow. School of Psychology, Faculty of Health and Medical Sciences, University of Adelaide
-
Adjunct Professor, Murdoch University
-
ARC Future Fellow, Australian National University
-
Associate Professor, School of Law, University of Canberra
-
HERA Program Director - Health Workforce Optimisation Centre for the Business & Economics of Health, The University of Queensland
-
Adjunct Research Fellow, The University of Western Australia
-
Associate Professor of Law, Bond University
